FMS-like tyrosine kinase 3 (FLT3) gene mutations have been found in more than one-third of
Acute Myeloid Leukemia (AML) cases. The most common point mutation in FLT3 occurs at …

FMS-like tyrosine kinase 3 (FLT3) serves as an important drug target for acute myeloid
leukemia (AML), and gene mutations of FLT3 have been closely associated with AML …

Abstract Over 30–35% of patients down with AML are caused by mutations of FLT3‐ITD and
FLT3‐TKD which keeps the protein activated while it activates other signaling proteins …

FLT3 mutations are the most common genomic alteration detected in acute myeloid
leukemia (AML) with a worse clinical prognosis. The highly frequent FLT3 mutations …

More than one-third of patients with acute myeloid leukemia (AML) harbor aberrant
mutations in Fms-like tyrosine kinase 3 (FLT3). Among them, the internal tandem duplication …

Acute myeloid leukemia is an aggressive cancer, which, in spite of increasingly better
understanding of its genetic background remains difficult to treat. Mutations in the FLT3 gene …

ABSTRACT Mutations in Fetal Liver Tyrosine Kinase 3 (FLT3) genes are implicated in the
constitutive activation and development of Acute Myeloid Leukaemia (AML). They are …

Acute myeloid leukemia (AML) is a malignant disease characterized by abnormal growth
and differentiation of hematopoietic stem cells. Although the pathogenesis has not been fully …

FLT3 is considered a potential target of acute myeloid leukemia therapy. In this study, we
applied a computer-aided methodology unifying molecular docking and pharmacophore …

Activating mutations in FMS-like tyrosine kinase 3 (FLT3) occur in 25% of acute lymphoid
and 30% of acute myeloid leukaemia cases. Therefore, FLT3 is a potential therapeutic target …